dendritic cell

(redirected from Plasmacytoid dendritic cell)
Also found in: Dictionary, Medical.

dendritic cell

[den′drid·ik ¦sel]
(cell and molecular biology)
A specialized cell of the lymphoid reticuloendothelial system that presents antigens for detection by lymphocytes.
References in periodicals archive ?
5] The epithelioid cells in human tuberculoid leprosy are CD123-positive, indicating that they are plasmacytoid dendritic cells.
2007) Plasmacytoid dendritic cells employ multiple cell adhesion molecules sequentially to interact with high endothelial venule cells--molecular basis of their trafficking to lymph nodes.
Hepatitis B virus suppresses the functional interaction between natural killer cells and plasmacytoid dendritic cells.
Clinicopathological features and prognostic significance of CXCL12 in blastic plasmacytoid dendritic cell neoplasm.
The plasmacytoid dendritic cells induce psoriasis through IFN-[alpha] production, infiltrating the skin in early phase of psoriasis [2].
Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms.
The Leukemia & Lymphoma Society is investing USD3m to support this effort and is also providing a comprehensive educational programme to increase physician and patient awareness of blastic plasmacytoid dendritic cell neoplasm.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic cancer for which there is no effective treatment, carries a poor prognosis and represents an unmet medical need.
Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals.
IMGN632 is a CD123-targeted ADC for hematological malignancies, including AML and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
STML) announced the opening of its SL-401 Investigational New Drug (IND) and initiation of a clinical development program including trials in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).